News

For his research efforts to better understand the molecular pathways that are responsible for axonal degeneration in glaucoma, Richard Libby, PhD, was awarded the 2017 Shaffer Prize for Research during Thursday night’s Glaucoma 360 annual Gala.

Over the years, Glaucoma 360 has brought the concept of innovation in glaucoma to the forefront. This year’s meeting will surpass the Glaucoma Research Foundation’s (GRF) own “Horizons” by adding a few more “degrees” to its 360-degree concept.

A renowned ophthalmologist and an accomplished opera singer were the highlight of Thursday night’s Glaucoma 360 annual Gala, when the two were presented with the Glaucoma Research Foundation’s (GRF) highest honors-The Catalyst Award and Visionary Award.

Since making the switch to a markerless toric alignment system, Bryan S. Lee, MD, JD, explains how the technology has eliminated ink marking from his surgical regimen.

Phenylephrine 1%/ketorolac injection 0.3% added to ophthalmic irrigation solution and administered intracamerally during cataract surgery was associated with a statistically significant reduction in surgical time, intraoperative complications, and use of pupil dilating devices and with a statistically significant improvement in best-corrected visual acuity.

A sophisticated integrated formula for IOL power prediction is the featured capability in upgrades to Clarity Medical Systems’ intraoperative wavefront aberrometer.

An intraoperative injection of a compounded formulation of triamcinolone acetonide, moxifloxacin, and vancomycin eliminated the need for supplemental postoperative medications in the vast majority of patients who underwent phacoemulsification and IOL implantation.

When his surgery center was in the market for a new phacoemulsification platform, medical director Jonathan Solomon, MD, decided to switch from a unit equipped with a flow-based peristaltic pump to technology that features a vacuum-based Venturi system (Stellaris PC, Bausch + Lomb).

Dr. David Chang, M.D. describes his experience with ZEISS Cataract Suite markerless.

I see the beginning of 2017 as fresh. A year of fresh possibilities. It is new and brimming with fresh beginnings, filled with hopes and dreams. If you are not feeling it, perhaps you are ensnared in the gray world of A, B, and C. This ABC is a continuous loop. You are not sure how you got there or how to get out.

Consider factors such as glaucoma severity, eye pigmentation, and medication use when selecting power settings for the MicroPulse P3 device.

Patients with cataract surgery and microstent implantation had a lowered IOP and a reduced number of medications used at 3 years postoperatively

Recent tooth loss and periodontal disease have been linked to primary open-angle glaucoma in a large prospective study of male health professionals.

Netarsudil ophthalmic solution 0.02% met its primary and secondary efficacy endpoints in a third phase III trial investigating its non-inferiority to timolol maleate 0.05% for IOP lowering.

A new add-on glaucoma module has the capability of creating an anatomic map of each patient’s eye by using two fixed landmarks. The module also includes an extensive reference data base.

New laser technology in a single device offers multiple treatment platforms, including SLT for glaucoma, laser vitreolysis for floaters, capsulotomy, and iridotomy.

Though much focus for stents has been in the trabecular meshwork, many companies are currently developing suprachorodial devices, which are in various stages of FDA review.

A new 0.075% formulation of bromfenac ophthalmic solution (BromSite, Sun Pharma) could provide relief from pain and inflammation associated with cataract surgery.

Five patients receiving an extended-release travoprost delivery system (ENV515, Envisia Therapeutics) in the anterior chamber have ongoing IOP-lowering with follow-up to 9 months in an ongoing study.

Topical cyclosporine may be useful for treating dry eyes associated with immunomodulatory agents like nivolumab, which markedly upregulate T cell activation. In caring for patients with ocular side effects associated with cancer treatment, the delivery of proper ophthalmic care is critical.

In preparing for the new year, Editorial Advisory Board members of Ophthalmology Times weighed in on a few questions about their predictions for how 2017 will impact ophthalmology as a specialty.

The great thing about making predictions is that it is basically a win-win proposition: if you are correct in your predictions, you are celebrated for being a sage. If you are incorrect, you have the opportunity to learn from them and make better predictions for the next year. Wishing everyone a Happy New Year and a successful 2017!

Here is your roundup of what made top news in 2016!